Listed

Arbutus Biopharma Corp: Form 10-Q for the period ended Mar 31, 2014

Filed with the SEC on May 14, 2014 and accepted by EDGAR at May 14, 2014, 17:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-01-01 to 2014-03-31$4.4mus-gaap:Revenues
Research and development3 months2014-01-01 to 2014-03-31$8.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2014-01-01 to 2014-03-31−$6.0mus-gaap:OperatingIncomeLoss
Net income3 months2014-01-01 to 2014-03-31−$18.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2014-01-01 to 2014-03-31−$0.91us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2014-01-01 to 2014-03-31$9.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2014-01-01 to 2014-03-31$335.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2014-03-31$134.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-03-31$137.0mus-gaap:AssetsCurrent
Total assetsAt period end2014-03-31$138.5mus-gaap:Assets
Current liabilitiesAt period end2014-03-31$23.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2014-03-31$33.0mus-gaap:Liabilities
Shareholders' equityAt period end2014-03-31$105.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-14-002374. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.